A share price of NewAmsterdam Pharma Company NV [NAMS] is currently trading at $37.15, up 0.27%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 14.38% over the last week, with a monthly amount glided 53.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on August 25, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $45. Previously, Goldman started tracking the stock with Neutral rating on July 17, 2025, and set its price target to $27. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $42 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $44 on June 10, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $42 as its price target on June 04, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 30, 2024, and assigned it a price target of $48. In a note dated May 15, 2024, TD Cowen initiated an Buy rating.
NewAmsterdam Pharma Company NV experienced fluctuations in its stock price throughout the past year between $14.06 and $37.07. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $37.15 at the most recent close of the market. An investor can expect a potential return of 21.13% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
Trailing Twelve Months sales for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] were 64.01M which represents 740.06% growth. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -2.59%, and Net Profit Margin reading is -2.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NewAmsterdam Pharma Company NV [NASDAQ:NAMS] is 21.08. Also, the Quick Ratio is 21.08, while the Cash Ratio stands at 15.44. Considering the valuation of this stock, the price to sales ratio is 65.37, the price to book ratio is 5.37.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Sep 15 ’25 when 660.0 shares were purchased. Chief Accounting Officer, Kooij Louise Frederika completed a deal on Sep 09 ’25 to sell 0.15 million shares. Meanwhile, Director Topper James N bought 1260.0 shares on Sep 08 ’25.
